SELLAS Life Sciences Group Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
SLS$8.58+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit# | Description | Form | Exhibit | Filing Date |
|---|---|---|---|---|
| 3.1 | Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.) amended as of December 27, 2017 | 10-K | 3.1 | April 13, 2018 |
| 3.2 | Amended and Restated By-Laws of the Registrant | 8-K | 3.3 | January 5, 2018 |
| 4.1 | Form of Common Warrant issued in connection with January 2024 Offering | 8-K | 4.2 | January 8, 2024 |
| 4.2 | Form of Pre-Funded Warrant issued in connection with January 2024 Offering | 8-K | 4.1 | January 8, 2024 |
| 4.3 | Form of Common Warrant issued in connection with March 2024 Registered Direct Offering | 8-K | 4.2 | March 15, 2024 |
| 4.4 | Form of Pre-Funded Warrant issued in connection with March 2024 Registered Direct Offering | 8-K | 4.1 | March 15, 2024 |
| 10.1 | Form of Placement Agency Agreement entered into in connection with January 2024 Offering | 8-K | 1.1 | January 8, 2024 |
| 10.2 | Form of Securities Purchase Agreement, dated as of January 8, 2024, by and among SELLAS Life Sciences Group, Inc. and the purchasers party hereto. | 8-K | 10.1 | January 8, 2024 |
| 10.3 | Form of Placement Agency Agreement entered into in connection with March 2024 Registered Direct Offering | 8-K | 1.1 | March 15, 2024 |
| 10.4 | Form of Securities Purchase Agreement, dated as of March 15, 2024, by and among SELLAS Life Sciences Group, Inc. and the purchasers party hereto. | 8-K | 10.1 | March 15, 2024 |
| 31.1 | Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.** | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.** | |||
| 32.1 | Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *** | |||
| 32.2 | Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *** | |||
| 101.INS | XBRL Instance Document.* | |||
| 101.SCH | XBRL Taxonomy Extension Schema.* | |||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase.* | |||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase.* | |||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase.* | |||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase.* | |||
| * | Indicates management contract or compensatory plans or arrangements. |
|---|---|
| ** | Filed herewith |
| *** | The certifications attached as Exhibit 32.1 and Exhibit 32.2 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.